文献速递肿瘤 PET/CT

复发性前列腺癌患者68Ga-PSMA-11 PET/CT阴性后观察期间重复扫描阳性的临床影响因素:单中心回顾性研究

Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
PubMed 文献 · J Nucl Med · 2024-10-01

该单中心回顾性分析纳入2016年10月至2021年6月在UCLA因复发性前列腺癌接受至少2次68Ga-PSMA-11 PET/CT且首次扫描阴性、两次扫描间未接受前列腺癌相关治疗的患者,比较重复扫描阳性与阴性组的临床参数。结果显示重复扫描阳性组血清PSA水平、PSA绝对差值、PSA变化百分比、PSA速率均更高,PSA倍增时间更短。

要点

  • 重复68Ga-PSMA-11 PET/CT阳性组PSA中位数1.8 ng/mL,阴性组1.1 ng/mL(P=0.015)。
  • 阳性组PSA速率中位数0.044 ng/mL/周,阴性组0.017 ng/mL/周(P=0.002)。
  • 阳性组PSA倍增时间中位数5.1个月,阴性组8.3个月(P=0.006)。

核心结论

  • 首次68Ga-PSMA-11 PET/CT阴性后观察的复发性前列腺癌患者中,血清PSA明显升高且PSA倍增时间较短者重复扫描更可能阳性。

研究设计与样本

  • 单中心回顾性分析纳入2016年10月至2021年6月在UCLA因复发性前列腺癌接受至少2次68Ga-PSMA-11 PET/CT(PET1和PET2)且PET1阴性、两次扫描间未接受前列腺癌相关治疗的患者。
  • 最终分析纳入70例患者的83组两次PET/CT扫描,采用前列腺癌分子影像标准化评价标准定义阴性和阳性扫描。

主要发现

  • 83组扫描中PET2阴性39组(47%),PET2阳性44组(53%)。
  • 全部83组(100%)扫描从PET1至PET2 PSA均升高,PET1中位PSA 0.4 ng/mL(四分位距0.2-1.0),PET2中位PSA 1.6 ng/mL(四分位距0.9-3.8)。
  • PET2阳性组较阴性组PET2血清PSA更高(中位数1.8 vs. 1.1 ng/mL;P=0.015),PSA绝对差值更大(中位数1.4 vs. 0.7 ng/mL;P=0.006)。
  • PET2阳性组较阴性组PSA变化百分比更高(中位数+270.4% vs. +150.0%;P=0.031),PSA速率更高(中位数0.044 vs. 0.017 ng/mL/周;P=0.002),PSA倍增时间更短(中位数5.1 vs. 8.3个月;P=0.006)。

关键数值与推荐

  • PET2 PSA截断值4.80 ng/mL(灵敏度34%;特异度92%;AUC 0.66)。
  • PSA绝对差值截断值0.95 ng/mL(灵敏度62%;特异度71%;AUC 0.68)。
  • PSA变化百分比截断值阳性289.50%(灵敏度48%;特异度82%;AUC 0.64)。
  • PSA速率截断值0.033 ng/mL/周(灵敏度57%;特异度80%;AUC 0.70)。
  • PSA倍增时间截断值7.91个月(灵敏度71%;特异度62%;AUC 0.67)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This analysis aimed to identify clinical factors associated with positivity on repeat 68Ga-PSMA-11 PET/CT after a negative scan in patients with recurrent prostate cancer (PCa) under observation. Methods: This single-center, retrospective analysis included patients who underwent at least 2 68Ga-PSMA-11 PET/CT scans (PET1 and PET2) at UCLA between October 2016 and June 2021 for recurrent PCa with negative PET1 and no PCa-related treatments between the 2 scans. Using Prostate Cancer Molecular Imaging Standardized Evaluation criteria to define negative and positive scans, the final cohort was divided into PET2-negative (PET2-Neg) and PET2-positive (PET2-Pos). The same PET1 was used twice in the more than 2 PET cases with inclusion criteria fulfilled. Patient characteristics and clinical parameters were compared between the 2 cohorts using Mann-Whitney U test and Fisher exact test. Areas under the curve (AUCs) of the receiver operating characteristic and the Youden index were computed to determine the discrimination ability of statistically significant factors and specific cut points that maximized sensitivity and specificity, respectively. Results: The final analysis included 83 sets of 2 PET/CT scans from 70 patients. Thirty-nine of 83 (47%) sets were PET2-Neg, and 44 of 83 (53%) sets were PET2-Pos. Prostate-specific antigen (PSA) increased from PET1 to PET2 for all 83 (100%) sets of scans. Median PSA at PET1 was 0.4 ng/mL (interquartile range, 0.2-1.0) and at PET2 was 1.6 ng/mL (interquartile range, 0.9-3.8). We found higher serum PSA at PET2 (median, 1.8 vs. 1.1 ng/mL; P = 0.015), absolute PSA difference (median, 1.4 vs. 0.7 ng/mL; P = 0.006), percentage of PSA change (median, +270.4% vs. +150.0%: P = 0.031), and median PSA velocity (0.044 vs. 0.017 ng/mL/wk, P = 0.002) and shorter PSA doubling time (DT; median, 5.1 vs. 8.3 mo; P = 0.006) in the PET2-Pos cohort than in the PET2-Neg cohort. Receiver operating characteristic curves showed cutoffs for PSA at PET2 of 4.80 ng/mL (sensitivity, 34%; specificity, 92%; AUC, 0.66), absolute PSA difference of 0.95 ng/mL (sensitivity, 62%; specificity, 71%; AUC, 0.68), percentage of PSA change of a positive 289.50% (sensitivity, 48%; specificity, 82%; AUC, 0.64), PSA velocity of 0.033 ng/mL/wk (sensitivity, 57%; specificity, 80%; AUC, 0.70), and PSA DT of 7.91 mo (sensitivity, 71%; specificity, 62%; AUC, 0.67). Conclusion: Patients with recurrent PCa under observation after a negative 68Ga-PSMA-11 PET/CT scan with markedly elevated serum PSA levels and shorter PSA DT are more likely to have positive findings on repeat 68Ga-PSMA-11 PET/CT.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Thin P, Hotta M, Gafita A, et al. Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study. J Nucl Med. 2024. PMID: 39168522. doi:10.2967/jnumed.124.267591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。